Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | STK11 inact mut |
| Therapy | Vistusertib |
| Indication/Tumor Type | lung non-small cell carcinoma |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| STK11 inact mut | lung non-small cell carcinoma | no benefit | Vistusertib | Phase II | Actionable | In a Phase II trial, Vistusertib (AZD2014) did not result in a clinically relevant objective response rate (OR) or durable clinical benefit (DCB) in STK11-deficient non-small cell lung cancer patients, with an OR of 9.8% (2/26, 2 partial responses) and DCB of 24.4% (6/26) in those with KRAS co-mutations, and OR of 0% (0/17) and DCB of 14.6% (2/17) in KRAS wild-type patients, and led to feedback reactivation of Akt signaling in STK11-deficient lung cancer cell lines in culture (PMID: 40069402; NCT02664935). | 40069402 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40069402) | A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer. | Full reference... |